An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia to Present at Upcoming Investor Conferences in March
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) management to participate in investor conferences in March, including TD Cowen 44th Annual Health Care Conference, Barclays 26th Annual Global Healthcare Conference, and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Webcasts of the presentations will be available on the company's website.
Positive
None.
Negative
None.
OXFORD, England--(BUSINESS WIRE)--
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March:
TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts
Barclays 26th Annual Global Healthcare Conference. Fireside chat on Tuesday, March 12, 2024 at 1:05 p.m. EDT (5:05 p.m. GMT) in Miami, Florida
KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Fireside chat on Tuesday, March 19, 2024 at 2:15 p.m. EDT (6:15 p.m. GMT), virtual
Live webcasts of the presentations will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. For more information visit us on www.exscientia.ai or follow us on LinkedIn @ex-scientia and X @exscientiaAI.
When will Exscientia plc management participate in the TD Cowen 44th Annual Health Care Conference?
Exscientia plc management will participate in a fireside chat on Wednesday, March 6, 2024, at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts.
Where will the fireside chat at the Barclays 26th Annual Global Healthcare Conference take place?
The fireside chat at the Barclays 26th Annual Global Healthcare Conference will be on Tuesday, March 12, 2024, at 1:05 p.m. EDT (5:05 p.m. GMT) in Miami, Florida.
How can investors access the webcasts of the presentations?
Investors can access the webcasts of the presentations on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai.
For how long will archived replays of the webcasts be available?
Archived replays of the webcasts will be available for approximately 30 days following the presentation.
at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
